FDA Panel Rejects Hemispherx's Ampligen For Chronic Fatigue Syndrome; Stock Down

Friday, 21 December 2012

WASHINGTON (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) announced the outcome of the meeting of the Arthritis Advisory Committee of the U.S. Food and Drug Administration on the New Drug Application...

» Full news story

Other recent news in Markets

Growth, Growth, And More Growth: Yahoo's Mayer And Tumblr's Karp Talk Deal

Why Costco Stock Keeps Rising

Apple's Low Tax Rate Not Our Fault, Ireland Says

Lowe's to Donate $1 Million to Help Communities Impacted by Tornadoes

Autozone Cruises Uphill on Successful Third Quarter

Xbox One Announced as Microsoft Takes on Sony's PlayStation 4

Tornado Season: Do You Have Good Home Insurance?

Marks & Spencer misery with another change at top

New York's 10 Most Important Banks

UnitedHealthcare Brings Clinically Proven Diabetes Prevention and Control Programs to Los Angeles Co

Twitter

There don't appear to be any related tweets.
Be the first to tweet the news!

Our Facebook Page
LIKE us now:

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy

Send us your feedback |

LIKE us on Facebook

FIND us on Google+

Switch to U.S. version

FDA Panel Rejects Hemispherx's Ampligen For Chronic Fatigue Syndrome; Stock Down

Other recent news in Markets

Twitter

Current Topics

Local News

Staff Stories